Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis

Abstract

Background The comparative efficacy and safety of pharmacological agents to lower blood pressure in adults with diabetes and kidney disease remains controversial. We aimed to investigate the benefits and harms of blood pressure-lowering drugs in this population of patients. Methods We did a network meta-analysis of randomised trials from around the world comparing blood pressure-lowering agents in adults with diabetic kidney disease. Electronic databases (the Cochrane Collaboration, Medline, and Embase) were searched systematically up to January, 2014, for trials in adults with diabetes and kidney disease comparing orally administered blood pressure-lowering drugs. Primary outcomes were all-cause mortality and end-stage kidney disease. We also assessed secondary safety and cardiovascular outcomes. We did random-effects network meta-analysis to obtain estimates for primary and secondary outcomes and we presented these estimates as odds ratios or standardised mean differences with 95% CIs. We ranked the comparative effects of all drugs against placebo with surface under the cumulative ranking (SUCRA) probabilities. Findings 157 studies comprising 43,256 participants, mostly with type 2 diabetes and chronic kidney disease, were included in the network meta-analysis. No drug regimen was more effective than placebo for reducing all-cause mortality. However, compared with placebo, end-stage renal disease was significantly less likely after dual treatment with an angiotensin-recepto…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)62459-4

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 2

  1. 2013, KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease: chapter 1—definition and classification of CKD, Kidney Int Suppl, 3, 1
  2. Salanti, 2012, Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool, Res Synth Methods, 3, 80, 10.1002/jrsm.1037 · DOI · Paper page

Cited by

See all 399

Metadata

Authors
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M.
Affiliations
  • University of Otago (NZ)
  • University of Ioannina (GR)
  • Nicolaus Copernicus University (PL)
  • The University of Sydney (AU)
  • University of Calgary (CA)
  • University of Alberta (CA)
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • The Royal Free Hospital (GB)
Corresponding author
Strippoli, Giovanni F M
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-05
Volume
385
Issue
9982
Pages
2047-2056
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2162304120
Cited by
395
References
34
Citations by year
2026: 8 · 2025: 26 · 2024: 15 · 2023: 25 · 2022: 23 · 2021: 38 · 2020: 38 · 2019: 52 · 2018: 46 · 2017: 47 · 2016: 59 · 2015: 18
FWCI
8.94
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Funders
Canterbury Medical Research Foundation
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
blood pressure lowering agents, diabetic nephropathy, chronic kidney disease, type 2 diabetes, ACE inhibitors, angiotensin receptor blockers, end-stage renal disease, all-cause mortality, hyperkalemia, acute kidney injury, cardiovascular outcomes, drug safety
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Nephropathies, Humans, Hypertension, Kidney Failure, Chronic, Middle Aged, Randomized Controlled Trials as Topic, Treatment Outcome, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(14)62459-4
The paper
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015). Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(14)62459-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.